Table 2.
Information on cumulative genotypic resistance testing among 85 people living with HIV/AIDS at the time of switch to a 2-drug-regimen consisting of DOR + DTG (doravirine + dolutegravir, “DoDo”)
| Total N = 85 | n | (%) |
|---|---|---|
| Resistance testing information | ||
| Results available | 66 | 77.6% |
| Testing never performed | 9 | 10.6% |
| No information available | 10 | 11.8% |
| Reverse transcriptase | ||
| Any mutation documented | 57 | 67% |
| RAM affecting currently approved NRTI | 43 | 51% |
| RAM affecting currently approved NNRTI | 30 | 35% |
| DOR-RAM: algrothm-specific interpretation | ||
| GRADE 01/2023a | ||
| Flagged mutation(s) (S) | 21 | 25% |
| Resistance (R) | 1 | 1% |
| ANRS 33_10/2022a | ||
| Possible resistance (I) | 4 | 5% |
| Resistance (R) | 2 | 2% |
| HIVDB 9.4a | ||
| Low level/intermediate resistance (score 15–40) (I) | 9 | 11% |
| High level resistance (score ≥ 60) (R) | 2 | 2% |
| Integrase | ||
| Any mutation documented | 4 | 5% |
| RAM affecting DTG | 2 | 2% |
| N155H (algorithm-specific interpretation:) | 1 | 1% |
| GRADE 01/2023a | DTG qd: Intermediate (I), DTG bid: Flagged mutation (S) | |
| ANRS 33_10/2022a | DTG qd: Resistance (R), DTG bid: Susceptible (S) | |
| HIVDB 9.4a | Potential Low-Level Resistance (Score: 10) (S) | |
| Rega 10.0.0a | Susceptible GSS 1 (Score: 0.5) (S) | |
| L74I, T97A (algorithm-specific interpretation:) | 1 | 1% |
| GRADE 01/2023a | Flagged mutations (S) | |
| ANRS 33_10/2022a | Susceptible (S) | |
| HIVDB 9.4a | Susceptible (S) | |
| Rega 10.0.0a | Susceptible GSS 1 (Score: 0.25) (S) | |
| Protease | ||
| Any mutation reported | 48 | 56% |
| RAM affecting currently approved PI | 43 | 51% |
| Tropism testing | ||
| Test results available | N = 16 | (%)b |
| CCR5 | 9 | 56% |
| Dual/mixed | 1 | 6% |
| CXCR4 | 6 | 38% |
RAM resistance associated mutation, NRTI nucleoside/nucleotide reverse transcriptase inhibitors, NNRTI non-nucleoside reverse transcriptase inhibitors, DOR doravirine, GRADE Genotypic Resistance-Algorithm Deutschland [17]. (S), susceptible, (R) resistance, ANRS Agence Nationale de Recherche sur le Sida resistance algorithm, (I) intermediate, HIVDB Stanford HIV drug resistance database, DTG dolutegravir, qd once daily, bid twice daily, Rega Rega institute HIV-1 subtyping tool, PI protease inhibitors, CCR5 C–C-motif chemokine receptor type 5, CXCR4 C-X-C-motif chemokine receptor type 4
aAll genotypic resistance interpretation algorithms were accessed via the GRADE website[17]
bBased on the observed data